Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Merck & Co., Inc. (MRK) vs Tesla, Inc. (TSLA) Price & Performance

Merck & Co., Inc.Trade
Tesla, Inc.Trade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs Tesla, Inc. — how do they compare? Merck & Co., Inc. trades at $133.6 (market cap $321.77B), while Tesla, Inc. trades at $326.53 (market cap $1.31T). The key difference: Tesla, Inc. is far larger — about 4.1× Merck & Co., Inc.'s market cap, and Merck & Co., Inc. pays a 2.61% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals.

MRKTSLA
Market Cap
$321.77B$1.31T
Sector
HealthConsumer Cyclical
52-Week High
$131.84$489.88
52-Week Low
$77.60$298.16
Enterprise Value
$368.53B$1.29T
Dividend Yield
2.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.

Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.

Tesla, Inc.

Tesla (TSLA) trades at $326.58, down 1.3% over the past 24 hours, with a bearish technical signal driven by moving averages. The stock shows elevated valuation ratios, including a P/E of 308.16 and P/S of 11.36, while recent earnings performance was mixed with a Q2 2026 miss. Cash flow trends indicate heavy capital expenditure, and revenue growth has slowed, with net income margin at 3.67% for 2025. Recent news highlights regulatory approval for driver-assistance software in Europe and discussions on Tesla's strategic pivot toward AI and robotics.

Tesla faces near-term headwinds from valuation concerns and competitive pressures, but long-term growth potential hinges on autonomous driving technology and energy segment expansion. Key risks include execution challenges in new business lines and macroeconomic sensitivity. Analyst consensus is mixed with a $393.87 price target, suggesting cautious optimism amid high volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK

About Tesla, Inc.

Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.

Read more on TSLA